Differentiated GPCR assets, with the evidence attached
With InterAx Deep Signal™ we found better mechanisms on several targets, built better candidates for them, and out-licensed one program in a co-development deal.
| Program | Indication | Modality | Stage | Status |
|---|---|---|---|---|
| GLP-1 | Obesity, type 2 diabetes; neurodegeneration thesis | Oral small molecule | Preclinical, in vivo data. IND targeted Q4 2027 | In-house |
| Metabolic program (undisclosed target) | Obesity | Oral small molecule | Preclinical | Partnered |
| CNS program (undisclosed indication) | Undisclosed | Oral small molecule | Discovery | Discovery |
| Inflammation and autoimmune disorders | Inflammatory and autoimmune disorders | Oral small molecule | Discovery | Discovery |
Milestones: Q4 2027 GLP-1 IND filed, then first-in-human · Q4 2028 GLP-1 first-in-human completed · Q1 2030 GLP-1 Phase 2 completed. Milestones are targets and may change. See the legal notice.
An oral small molecule designed to match the injectable peptides.
Injectable GLP-1 receptor agonists set the standard for weight loss and glycemic control, a USD 62.9 billion market in 2025 growing 17.5% a year (Market.us). Oral small molecules have so far fallen short of them on efficacy and gastrointestinal tolerability. Deep Signal identified what gives the injectable peptides their efficacy and tolerability: a signaling profile that no oral small molecule reported so far has matched. Our series is designed to that profile.
Next milestone: IND filing in Q4 2027.
- Potency. EC50 of 0.14 nM after 30 compounds in four months, 10x the potency of the leading oral clinical comparator.
- Efficacy in diabetes. Insulin secretion up 70% versus the same comparator in diabetic cells (p<0.0001); efficacy matched the injectable peptide standard in hGLP1R mice.
- Tolerability by design. Signaling parameters fitted on six clinical compounds explain their gastrointestinal side effects (R² ≥ 0.8).
Neurodegeneration thesis
GLP-1 receptor activation in microglia is anti-inflammatory in the brain, but peptides barely cross the blood-brain barrier. A brain-penetrant oral small molecule with the right signaling profile is the missing piece, and our lead series is designed to that profile.
A partnered program that validates the platform.
Our second metabolic program, an oral small molecule for obesity at an undisclosed target, is partnered with Alveus Therapeutics, which funds its development. Alveus, founded by former Novo Nordisk and Eli Lilly executives and based in Boston and Copenhagen, develops next-generation obesity treatments designed to sustain weight loss, with its lead program already in Phase 2.
Inflammation and autoimmune disorders: complex signaling, decoded.
Stage: Discovery.
Our second discovery area targets GPCRs whose complex signaling conventional discovery has not resolved; some have no optimized therapy at all. We decode that signaling, choose the functional profile first and design the chemistry to it. Next step: efficacy in an in vivo model of inflammation.
We select new targets on drug novelty, market size, developability and fit with our platform and expertise.